1887
  1. Home
  2. Eurosurveillance
  3. Volume 20, Issue 45, 12/Nov/2015
  4. Article
Research article Open Access
Like 0
Download

Abstract

Surveillance of circulating influenza strains for antiviral susceptibility is important to ensure patient treatment guidelines remain appropriate. Influenza A(H3N2) and A(H1N1)pdm09 virus isolates containing mutations at the Q136 residue of the neuraminidase (NA) that conferred reduced susceptibility to the NA inhibitor (NAI) zanamivir were detected during antiviral susceptibility monitoring. Interestingly, the mutations were not detectable in the viruses from respective clinical specimens, only in the cultured isolates. We showed that variant viruses containing the Q136K and Q136R NA mutations were preferentially selected in Madin-Darby canine kidney epithelial (MDCK) cells, but were less well supported in MDCK-SIAT1 cells and embryonated eggs. The effect of Q136K, Q136R, Q136H and Q136L substitutions in NA subtypes N1 and N2 on NAI susceptibility and in vitro viral fitness was assessed. This study highlights the challenges that cell culture derived mutations can pose to the NAI susceptibility analysis and interpretation and reaffirms the need to sequence viruses from respective clinical specimens to avoid misdiagnosis. However, we also demonstrate that NA mutations at residue Q136 can confer reduced zanamivir, peramivir or laninamivir susceptibility, and therefore close monitoring of viruses for mutations at this site from patients being treated with these antivirals is important.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2015.20.45.30060
2015-11-12
2024-04-20
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2015.20.45.30060
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/20/45/eurosurv-20-30060-5.html?itemId=/content/10.2807/1560-7917.ES.2015.20.45.30060&mimeType=html&fmt=ahah

References

  1. Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. Lancet. 2000;355(9206):827-35.  https://doi.org/10.1016/S0140-6736(99)11433-8  PMID: 10711940 
  2. Hurt AC, Ho HT, Barr I. Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitors. Expert Rev Anti Infect Ther. 2006;4(5):795-805.  https://doi.org/10.1586/14787210.4.5.795  PMID: 17140356 
  3. Hurt AC, Holien JK, Parker MW, Barr IG. Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses. Drugs. 2009;69(18):2523-31.  https://doi.org/10.2165/11531450-000000000-00000  PMID: 19943705 
  4. Colman PM, Varghese JN, Laver WG. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature. 1983;303(5912):41-4.  https://doi.org/10.1038/303041a0  PMID: 6188957 
  5. Yen H-L, Herlocher LM, Hoffmann E, Matrosovich MN, Monto AS, Webster RG, et al. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob Agents Chemother. 2005;49(10):4075-84.  https://doi.org/10.1128/AAC.49.10.4075-4084.2005  PMID: 16189083 
  6. Hurt AC, Nor’e SS, McCaw JM, Fryer HR, Mosse J, McLean AR, et al. Assessing the viral fitness of oseltamivir-resistant influenza viruses in ferrets, using a competitive-mixtures model. J Virol. 2010;84(18):9427-38.  https://doi.org/10.1128/JVI.00373-10  PMID: 20631138 
  7. Bloom JD, Gong LI, Baltimore D. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science. 2010;328(5983):1272-5.  https://doi.org/10.1126/science.1187816  PMID: 20522774 
  8. Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, Mercier CH, et al. Neuraminidase Inhibitor Flu Treatment Investigator Group. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Lancet. 2000;355(9218):1845-50.  https://doi.org/10.1016/S0140-6736(00)02288-1  PMID: 10866439 
  9. Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, et al. US Oral Neuraminidase Study Group. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA. 2000;283(8):1016-24.  https://doi.org/10.1001/jama.283.8.1016  PMID: 10697061 
  10. Whitley RJ, Hayden FG, Reisinger KS, Young N, Dutkowski R, Ipe D, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J. 2001;20(2):127-33.  https://doi.org/10.1097/00006454-200102000-00002  PMID: 11224828 
  11. Tamura D, Sugaya N, Ozawa M, Takano R, Ichikawa M, Yamazaki M, et al. Frequency of drug-resistant viruses and virus shedding in pediatric influenza patients treated with neuraminidase inhibitors. Clin Infect Dis. 2011;52(4):432-7.  https://doi.org/10.1093/cid/ciq183  PMID: 21248368 
  12. Hurt AC, Ernest J, Deng YM, Iannello P, Besselaar TG, Birch C, et al. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res. 2009;83(1):90-3.  https://doi.org/10.1016/j.antiviral.2009.03.003  PMID: 19501261 
  13. Meijer A, Lackenby A, Hungnes O, Lina B, van-der-Werf S, Schweiger B, et al. European Influenza Surveillance Scheme. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg Infect Dis. 2009;15(4):552-60.  https://doi.org/10.3201/eid1504.181280  PMID: 19331731 
  14. Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis. 1998;178(5):1257-62.  https://doi.org/10.1086/314440  PMID: 9780244 
  15. Wetherall NT, Trivedi T, Zeller J, Hodges-Savola C, McKimm-Breschkin JL, Zambon M, et al. Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J Clin Microbiol. 2003;41(2):742-50.  https://doi.org/10.1128/JCM.41.2.742-750.2003  PMID: 12574276 
  16. van der Vries E, Stelma FF, Boucher CA. Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. N Engl J Med. 2010;363(14):1381-2.  https://doi.org/10.1056/NEJMc1003749  PMID: 20879894 
  17. Nguyen HT, Fry AM, Loveless PA, Klimov AI, Gubareva LV. Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/I223R mutation from a child after prolonged treatment with oseltamivir. Clin Infect Dis. 2010;51(8):983-4.  https://doi.org/10.1086/656439  PMID: 20858074 
  18. Eshaghi A, Patel SN, Sarabia A, Higgins RR, Savchenko A, Stojios PJ, et al. Multidrug-resistant pandemic (H1N1) 2009 infection in immunocompetent child. Emerg Infect Dis. 2011;17(8):1472-4. PMID: 21801626 
  19. Okomo-Adhiambo M, Nguyen HT, Sleeman K, Sheu TG, Deyde VM, Garten RJ, et al. Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses. Antiviral Res. 2010;85(2):381-8.  https://doi.org/10.1016/j.antiviral.2009.11.005  PMID: 19917319 
  20. Hurt AC, Holien JK, Parker M, Kelso A, Barr IG. Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. J Virol. 2009;83(20):10366-73.  https://doi.org/10.1128/JVI.01200-09  PMID: 19641000 
  21. Hoffmann E, Krauss S, Perez D, Webby R, Webster RG. Eight-plasmid system for rapid generation of influenza virus vaccines. Vaccine. 2002;20(25-26):3165-70.  https://doi.org/10.1016/S0264-410X(02)00268-2  PMID: 12163268 
  22. Reading PC, Pickett DL, Tate MD, Whitney PG, Job ER, Brooks AG. Loss of a single N-linked glycan from the hemagglutinin of influenza virus is associated with resistance to collectins and increased virulence in mice. Respir Res. 2009;10(117):117.  https://doi.org/10.1186/1465-9921-10-117  PMID: 19930664 
  23. Leang S-K, Deng YM, Shaw R, Caldwell N, Iannello P, Komadina N, et al. Influenza antiviral resistance in the Asia-Pacific region during 2011. Antiviral Res. 2013;97(2):206-10.  https://doi.org/10.1016/j.antiviral.2012.12.016  PMID: 23274624 
  24. Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten RJ, Xu X, Bright RA, et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother. 2008;52(9):3284-92.  https://doi.org/10.1128/AAC.00555-08  PMID: 18625765 
  25. Escuret V, Collins PJ, Casalegno JS, Vachieri SG, Cattle N, Ferraris O, et al. A novel I221L substitution in neuraminidase confers high-level resistance to oseltamivir in influenza B viruses. J Infect Dis. 2014;210(8):1260-9.  https://doi.org/10.1093/infdis/jiu244  PMID: 24795482 
  26. Matrosovich M, Matrosovich T, Carr J, Roberts NA, Klenk HD. Overexpression of the α-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. J Virol. 2003;77(15):8418-25.  https://doi.org/10.1128/JVI.77.15.8418-8425.2003  PMID: 12857911 
  27. Eshaghi A, Shalhoub S, Rosenfeld P, Li A, Higgins RR, Stogios PJ, et al. Multiple influenza A (H3N2) mutations conferring resistance to neuraminidase inhibitors in a bone marrow transplant recipient. Antimicrob Agents Chemother. 2014;58(12):7188-97.  https://doi.org/10.1128/AAC.03667-14  PMID: 25246391 
  28. Hurt AC, Lowther S, Middleton D, Barr IG. Assessing the development of oseltamivir and zanamivir resistance in A(H5N1) influenza viruses using a ferret model. Antiviral Res. 2010;87(3):361-6.  https://doi.org/10.1016/j.antiviral.2010.06.009  PMID: 20603155 
  29. Govorkova EA, Ilyushina NA, Marathe BM, McClaren JL, Webster RG. Competitive fitness of oseltamivir-sensitive and -resistant highly pathogenic H5N1 influenza viruses in a ferret model. J Virol. 2010;84(16):8042-50.  https://doi.org/10.1128/JVI.00689-10  PMID: 20519385 
  30. Peng AW, Milleri S, Stein DS. Direct measurement of the anti-influenza agent zanamivir in the respiratory tract following inhalation. Antimicrob Agents Chemother. 2000;44(7):1974-6.  https://doi.org/10.1128/AAC.44.7.1974-1976.2000  PMID: 10858364 
  31. Calfee DP, Peng AW, Cass LM, Lobo M, Hayden FG. Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Antimicrob Agents Chemother. 1999;43(7):1616-20. PMID: 10390212 
  32. Kaminski MM, Ohnemus A, Staeheli P, Rubbenstroth D. Pandemic 2009 H1N1 influenza A virus carrying a Q136K mutation in the neuraminidase gene is resistant to zanamivir but exhibits reduced fitness in the guinea pig transmission model. J Virol. 2013;87(3):1912-5.  https://doi.org/10.1128/JVI.02507-12  PMID: 23192869 
  33. Pizzorno A, Abed Y, Rhéaume C, Bouhy X, Boivin G. Evaluation of recombinant 2009 pandemic influenza A (H1N1) viruses harboring zanamivir resistance mutations in mice and ferrets. Antimicrob Agents Chemother. 2013;57(4):1784-9.  https://doi.org/10.1128/AAC.02269-12  PMID: 23357777 
  34. Butler J, Hooper KA, Petrie S, Lee R, Maurer-Stroh S, Reh L, et al. Estimating the fitness advantage conferred by permissive neuraminidase mutations in recent oseltamivir-resistant A(H1N1)pdm09 influenza viruses. PLoS Pathog. 2014;10(4):e1004065.  https://doi.org/10.1371/journal.ppat.1004065  PMID: 24699865 
Zanamivir-resistant influenza viruses with Q136K or Q136R neuraminidase residue mutations can arise during MDCK cell culture creating challenges for antiviral susceptibility monitoring
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Karen+Little&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Little Karen</a>, <a href="/search?value1=Sook-Kwan+Leang&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Leang Sook-Kwan</a>, <a href="/search?value1=Jeff+Butler&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Butler Jeff</a>, <a href="/search?value1=Chantal+Baas&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Baas Chantal</a>, <a href="/search?value1=Bruce+Harrower&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Harrower Bruce</a>, <a href="/search?value1=Jenny+Mosse&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Mosse Jenny</a>, <a href="/search?value1=Ian+G+Barr&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Barr Ian G</a>, <a href="/search?value1=Aeron+C+Hurt&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Hurt Aeron C</a></span>. Zanamivir-resistant influenza viruses with Q136K or Q136R neuraminidase residue mutations can arise during MDCK cell culture creating challenges for antiviral susceptibility monitoring. <a href="/content/ecdc">Euro Surveill.</a> 2015;20(45):pii=30060. <a href="https://doi.org/10.2807/1560-7917.ES.2015.20.45.30060" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2015.20.45.30060</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 22 Feb 2015;&nbsp;&nbsp; <span class="generated">Accepted</span>: 24 Sept 2015 </span> </p>
/content/10.2807/1560-7917.ES.2015.20.45.30060
/content/10.2807/1560-7917.ES.2015.20.45.30060
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error